Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
AMPK mediates regulation of glomerular volume and podocyte survival
Khadija Banu, … , Barbara Murphy, Madhav C. Menon
Khadija Banu, … , Barbara Murphy, Madhav C. Menon
Published September 2, 2021
Citation Information: JCI Insight. 2021;6(19):e150004. https://doi.org/10.1172/jci.insight.150004.
View: Text | PDF
Research Article Cell biology Nephrology

AMPK mediates regulation of glomerular volume and podocyte survival

  • Text
  • PDF
Abstract

Herein, we report that Shroom3 knockdown, via Fyn inhibition, induced albuminuria with foot process effacement (FPE) without focal segmental glomerulosclerosis (FSGS) or podocytopenia. Interestingly, knockdown mice had reduced podocyte volumes. Human minimal change disease (MCD), where podocyte Fyn inactivation was reported, also showed lower glomerular volumes than FSGS. We hypothesized that lower glomerular volume prevented the progression to podocytopenia. To test this hypothesis, we utilized unilateral and 5/6th nephrectomy models in Shroom3-KD mice. Knockdown mice exhibited less glomerular and podocyte hypertrophy after nephrectomy. FYN-knockdown podocytes had similar reductions in podocyte volume, implying that Fyn was downstream of Shroom3. Using SHROOM3 or FYN knockdown, we confirmed reduced podocyte protein content, along with significantly increased phosphorylated AMPK, a negative regulator of anabolism. AMPK activation resulted from increased cytoplasmic redistribution of LKB1 in podocytes. Inhibition of AMPK abolished the reduction in glomerular volume and induced podocytopenia in mice with FPE, suggesting a protective role for AMPK activation. In agreement with this, treatment of glomerular injury models with AMPK activators restricted glomerular volume, podocytopenia, and progression to FSGS. Glomerular transcriptomes from MCD biopsies also showed significant enrichment of Fyn inactivation and Ampk activation versus FSGS glomeruli. In summary, we demonstrated the important role of AMPK in glomerular volume regulation and podocyte survival. Our data suggest that AMPK activation adaptively regulates glomerular volume to prevent podocytopenia in the context of podocyte injury.

Authors

Khadija Banu, Qisheng Lin, John M. Basgen, Marina Planoutene, Chengguo Wei, Anand C. Reghuvaran, Xuefei Tian, Hongmei Shi, Felipe Garzon, Aitor Garzia, Nicholas Chun, Arun Cumpelik, Andrew D. Santeusanio, Weijia Zhang, Bhaskar Das, Fadi Salem, Li Li, Shuta Ishibe, Lloyd G. Cantley, Lewis Kaufman, Kevin V. Lemley, Zhaohui Ni, John Cijiang He, Barbara Murphy, Madhav C. Menon

×

Figure 6

AMPK activation reduces Vglom and mitigates podocytopenia in aged Shroom3-KD mice with podocyte FPE.

Options: View larger image (or click on image) Download as PowerPoint
AMPK activation reduces Vglom and mitigates podocytopenia in aged Shroom...
Shroom3-KD and control mice were age 1 year or older and DOX fed for 6 weeks (n = 5 per group). (A) Representative WBs of kidney lysates probed for total and phosphorylated Ampk, Turbo-Gfp, and actin of young controls, aged controls, and aged Shroom3-KD mice. Dot plots show (B) blood urea nitrogen (mg/dl) in aged control and Shroom3-KD mice. (C) Dot plots show podocytes/glomerulus/animal, and box plots (line at median) show distribution of podocytes/glomerulus/group. (D) Vglom per group (×1000 μm3) between aged control and Shroom3-KD groups. (E) Representative PAS images of 2 glomeruli (63×) showing mesangial expansion in aged Shroom3-KD mice (bottom row) versus aged controls (top row). In subsequent experiments, metformin-water (MF) was added at week 2 of DOX to aged control/Shroom3-KD mice. (F) Dot plots compare albumin/creatinine ratio (μg/mg) at 6 weeks DOX in aged control versus aged Shroom3-KD mice, both with and without MF treatment. (G) Dot plots compare podocytes/glomerulus/animal and box plots (line at median) show distribution of podocytes/glomerulus/group and (H) Vglom (×1000 μm3) per group between aged control+MF and Shroom3-KD+MF groups. In the box-and-whisker plot, the box represents the middle quartiles, the lines indicate the median, and the whiskers denote the 5th–9th percentile. Line and whiskers indicate mean ± SEM; unpaired t test; *P < 0.05, **P < 0.01, ***P < 0.001; WB, Western blot; PAS, periodic acid–Schiff; WT1, Wilms’ tumor 1 protein; 30 glomerular profiles/animal were used for WT1 immunofluorescence; 10 glomeruli/animal were measured for Vglom).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts